Liver stiffness assessed by transient elastography (FibroScan®) (kPa)

ALT (U/L) and AST (U/L)

Total cholesterol (mg/dL), Triglycerides (mg/dL), HDL-C (mg/dL), Non-HDL-C (mg/dL), and LDL-C (mg/dL)

HbA1c (%)

C-Peptide (ng/mL)

Adiponectin (mg/L)

Insulin (mIU/L)

HOMA-IR (≥ 2.5 indicates insulin resistance)

Proportion of subjects reporting adverse events

Proportion of subjects reporting adverse events

Based on NASH CRN fibrosis score (scored by a fibrosis score of 0-4, where 0 = no fibrosis, 1 = centrilobular pericellular fibrosis, 2 = centrilobular and periportal fibrosis, 3 = bridging fibrosis, 4 = cirrhosis)

Based on NASH CRN fibrosis score (scored by a fibrosis score of 0-4, where 0 = no fibrosis, 1 = centrilobular pericellular fibrosis, 2 = centrilobular and periportal fibrosis, 3 = bridging fibrosis, 4 = cirrhosis)

Based on NAS (scored by 0-1 for steatosis, 0-3 for inflammation, and 0-2 for ballooning)

Based on NAS (scored by 0-1 for steatosis, 0-3 for inflammation, and 0-2 for ballooning) and NASH CRN fibrosis score (scored by a fibrosis score of 0-4, where 0 = no fibrosis, 1 = centrilobular pericellular fibrosis, 2 = centrilobular and periportal fibrosis, 3 = bridging fibrosis, 4 = cirrhosis)